
A new drug combination for advanced liver cancer can extend people’s lives substantially more than the long-standing drug of choice, new study findings confirm. The treatment involves two drugs approved to fight various cancers: bevacizumab (Avastin) and atezolizumab (Tecentriq). Avastin, an intravenous (IV) drug, starves tumors by preventing new blood vessel growth. Tecentriq, also given… read on > read on >